Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug
Physician's Weekly
JUNE 18, 2025
WEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics , a gene-editing startup, for about $1 billion upfront. Verve is developing a new class of gene-editing drugs that could be given just once to treat chronic conditions. The deal, announced June 17, includes a cash offer of $10.50
Let's personalize your content